Sector News

Mallinckrodt buys Ikaria for $2.3bn

March 6, 2015
Life sciences
Dublin, Ireland-based speciality biopharma Mallinckrodt is extending its hospital-based offering with a $2.3-billion purchase of US privately-held critical care group Ikaria.
 
A Mallinckrodt subsidiary will acquire the company from a Madison Dearborn-led investor group, with the transaction is expected to close early in the second quarter assuming closing conditions are satisfied.
 
The firm says the deal will further accelerate growth in its Specialty Brands segment, broaden its hospital presence, and diversify its portfolio with “high-value, high-margin critical care products”.
 
The move is expected to add at least $150 million in net sales and be accretive to Mallinckrodt’s fiscal year 2015 adjusted diluted earnings per share by at least $0.25 per share.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend